期刊文献+

因子设计-效应面法优化5-氨基水杨酸原位凝胶灌肠液处方

Formula Optimization of 5-Aminosalicylic Acid Enema In Situ Gel by Factorial Design/Response Surface Methodology
下载PDF
导出
摘要 目的:优化5-氨基水杨酸原位凝胶灌肠液处方。方法:以卡波姆作为凝胶基质,以黄原胶作为增稠剂,采用冷溶法制备具有pH敏感的5-氨基水杨酸原位凝胶灌肠液。采用3-2满因子设计试验,考察卡波姆、黄原胶的用量对原位凝胶灌肠液成胶前和成胶后粘度、倒置管试验持续时间以及沉降体积比等指标的影响,通过响应面法对处方进行优化。结果:2个影响因素和4个考察指标存在着定量关系。最优处方为:卡波姆和黄原胶在处方中的含量分别为0.7%和0.15%。按最优处方制备的5-氨基水杨酸原位凝胶灌肠液成胶前黏度为500-1 000 m Pa·s,成胶后黏度为2 200-2 700 m Pa·s,倒置管试验时间为40-80 min,沉降体积比大于98.5%。结论:通过因子设计-效应面法完成了5-氨基水杨酸原位凝胶灌肠液的多目标同步优化。 Objective: To optimize the formula of 5-aminosalicylic acid enema in situ gel. Methods: 5-Aminosalicylic acid enemas in situ gel was prepared using a cold dissolution method with earbomer as the gel matrix and xanthan gum as the thickener. A 32 full factorial design was used to investigate the effects of the concentrations of carbomer and xanthan gum on the viscosity before and after the gelling, duration of inversion tube and sedimentation rate. Response surface methodology was used to optimize the formula. Results : The quantitative relationships between the two factors and the four evaluation indices were obtained. The optimum formula was as follows: the concentration of carhopol and xanthan gum in the enema was 0.7% and 0.15%, respectively. The viscosity before and after the gelling was 500-1 000 mPa ·s and 2 200-2 700 mPa· s, respectively. The duration of inversion tube test was 40-80 min and the sedimentation rate was more than 98.5 %. Conclusion: The multi-objective simultaneous optimization of the formula of 5-aminosal- icylic acid enema in situ gel is accomplished by factorial design and response surface methodology.
出处 《中国药师》 CAS 2016年第2期287-289,305,共4页 China Pharmacist
基金 武汉市卫生局临床医学科研项目(编号:WX2D10)
关键词 5-氨基水杨酸 原位凝胶 灌肠液 因子设计 效应面法 5-Aminosalicylic acid In situ gel Enema Factorial design Response surface methodology
  • 相关文献

参考文献5

  • 1Sandborn WJ. Oral 5-ASA therapy in ulcerative colitis : what are the implications of the new formulations? [ J ]. J Clin Gastroenterol, 2008, 42(4) : 338-344.
  • 2Ingrid Ord6s, Lars Eckmann, Mark Talamini, et al. Ulcerative colitis [J]. The Lancet, 2012, 380(9853) : 1606-1619.
  • 3Marshall JK, Irvine EJ. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis [ J ]. Am J Gastroenterol, 2000, 95(7) : 1628-1636.
  • 4Travis SP. Review artele: induction therapy for patients with active ulcerative colitis[ J]. Aliment Pharmacol Ther, 2006, 24 (9) Suppl 1 : 10-16.
  • 5赵倩,彭丽君,周莉红,符旭东,陆媛媛,李雪梅.HPLC法测定5-氨基水杨酸灌肠液的含量及有关物质[J].中国药师,2014,17(9):1506-1510. 被引量:2

二级参考文献5

  • 1Sandborn WJ. Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations[ J]. J Clin C, astroenterol,2008 , 42(4) :338-44.
  • 2Marshall JK, Irvine EJ. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis [ J ]. Am J Gastroenterol. ,2000 ,95 ( 7 ) : 1628-36.
  • 3Sanborn WJ, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesaluzine prodrugs used in the management of ulcerative colitis [ J ]. Aliment Pharmacol Ther, 2003, 17 : 29 - 42.
  • 4江学良,崔慧斐.中国溃疡性结肠炎10218例的特点[J].世界华人消化杂志,2001,9(8):869-873. 被引量:67
  • 5李伟,程传玲,徐桂清.美沙拉秦中有机杂质的探讨[J].中国医药工业杂志,2002,33(11):554-557. 被引量:8

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部